Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 2, 2020
- Accepted in final form May 19, 2020
- First Published July 24, 2020.
Author Disclosures
- Luise Appeltshauser, MD,
- Anna-Michelle Brunder,
- Annika Heinius,
- Peter Körtvélyessy, MD,
- Klaus-Peter Wandinger, MD,
- Ralf Junker, MD,
- Carmen Villmann, PhD,
- Claudia Sommer, MD,
- Frank Leypoldt, MD and
- Kathrin Doppler, MD
- Luise Appeltshauser, MD,
NONE
NONE
NONE
NONE
NONE
NONE
L. Appeltshauser, K-P. Wandinger, R. Junker, C. Sommer, F. Leypoldt, and K.Doppler work for an academic institution offering commercial antibody diagnostics.
NONE
NONE
NONE
NONE
NONE
NONE
LA is supported by a research fellowship as a clinician scientist of the Interdisciplinary Center of Clinical Research of the Medical Faculty of Würzburg.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anna-Michelle Brunder,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Annika Heinius,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter Körtvélyessy, MD,
- Klaus-Peter Wandinger, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf Junker, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Carmen Villmann, PhD,
NONE
NONE
NONE
Associate editor - Frontiers in Molecular Neuroscience Associate editor - Biological Chemistry
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claudia Sommer, MD,
Algiax, Alnylam, Air Liquide, Akcea, Astellas Bayer, Grifols Takeda UCB
NONE
Akcea Alnylam Novartis Pfizer Sanofi-Aventis Teva
European Journal of Neurology PlosOne PainReports
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Research Foundation (DFG)328/9-1; 328/10-1 Bundesministerium für Bildung und Forschung (BMBF), CMT-Net not related to the current manuscript
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frank Leypoldt, MD and
(1) Roche, Biogen, Alexion
NONE
(1) Grifols (2) Teva (3) Biogen (4) Fresenius (5) Bayer (6) Novartis (6) Roche (6) Novartis (7) Merck (8) Roche (9) Alexion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Institute of Laboratory Medicine, University Hospital Schleswig- Holstein Campus Kiel, Germany, commercial antibody testing service, 20%
NONE
(1) German Ministry of Education and Research (BMBF) Speaker, PI 2019 01GM1908A (2) German Research Council (GRC, DFG), PI, 2019 LE 3064/2-1
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kathrin Doppler, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)German Research Foundation, DO 2219/1-1, 2018-2021 (2)Federal Ministry of Education and Research (BMBF), 2016-2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (L.A., A.-M.B., C.S., K.D.), University Hospital of Würzburg; Neuroimmunology Section (A.H., K.-P.W., R.J., F.L.), Institute of Clinical Chemistry, University Hospital of Schleswig-Holstein Campus Kiel; Department of Neurology (P.K.), University Hospital of Magdeburg; and Institute for Clinical Neurobiology (C.V.), University Hospital of Würzburg, Germany.
- Correspondence
Dr. Appeltshauser Appeltshau_L{at}ukw.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Anti–pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathyHelena Stengel, Atay Vural, Anna-Michelle Brunder et al.Neurology: Neuroimmunology & Neuroinflammation, August 16, 2019 -
Article
Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDPClinical relevance of IgG isotypeAndrea Cortese, Raffaella Lombardi, Chiara Briani et al.Neurology: Neuroimmunology & Neuroinflammation, November 21, 2019 -
Article
Anti–contactin-1 Antibodies Affect Surface Expression and Sodium Currents in Dorsal Root GangliaJulia Grüner, Helena Stengel, Christian Werner et al.Neurology: Neuroimmunology & Neuroinflammation, August 24, 2021 -
Null Hypothesis
Antibodies against nodo-paranodal proteins are not present in genetic neuropathiesLorena Martín-Aguilar, Elba Pascual-Goñi, Cinta Lleixà et al.Neurology, February 26, 2020